| A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors AM Scott, FT Lee, N Tebbutt, R Herbertson, SS Gill, Z Liu, E Skrinos, ... Proceedings of the National Academy of Sciences 104 (10), 4071-4076, 2007 | 308 | 2007 |
| Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice JA Westwood, MJ Smyth, MWL Teng, M Moeller, JA Trapani, AM Scott, ... Proceedings of the National Academy of Sciences 102 (52), 19051-19056, 2005 | 174 | 2005 |
| Novel monoclonal antibody specific for the de2‐7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene TG Johns, E Stockert, G Ritter, AA Jungbluth, HJS Huang, WK Cavenee, ... International journal of cancer 98 (3), 398-408, 2002 | 173 | 2002 |
| Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors AM Scott, D Geleick, M Rubira, K Clarke, EC Nice, FE Smyth, E Stockert, ... Cancer Research 60 (12), 3254-3261, 2000 | 152 | 2000 |
| A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake AM Scott, FT Lee, R Jones, W Hopkins, D MacGregor, JS Cebon, ... Clinical Cancer Research 11 (13), 4810-4817, 2005 | 147 | 2005 |
| Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ... The Lancet Oncology 19 (11), 1530-1542, 2018 | 129 | 2018 |
| The ERGB/Fli-1 gene: isolation and characterization of a new member of the family of human ETS transcription factors DK Watson, FE Smyth, DM Thompson, JQ Cheng, JR Testa, TS Papas, ... Cell growth and differentiation 3, 705-705, 1992 | 126 | 1992 |
| Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial AM Scott, FT Lee, W Hopkins, JS Cebon, JM Wheatley, Z Liu, FE Smyth, ... Journal of clinical oncology 19 (19), 3976-3987, 2001 | 108 | 2001 |
| Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor T Domagala, N Konstantopoulos, F Smyth, RN Jorissen, L Fabri, ... Growth factors 18 (1), 11-29, 2000 | 106 | 2000 |
| Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A ″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478 FT Lee, AJ Mountain, MP Kelly, C Hall, A Rigopoulos, TG Johns, ... Clinical cancer research 11 (19), 7080s-7086s, 2005 | 101 | 2005 |
| Immuno-PET of human colon xenograft–bearing BALB/c nude mice using 124I-CDR–grafted humanized A33 monoclonal antibody FT Lee, C Hall, A Rigopoulos, J Zweit, K Pathmaraj, GJ O’Keefe, ... Journal of Nuclear Medicine 42 (5), 764-769, 2001 | 98 | 2001 |
| Therapeutic Efficacy of Anti-Lewisy Humanized 3S193 Radioimmunotherapy in a Breast Cancer Model: Enhanced Activity When Combined with Taxol Chemotherapy K Clarke, FT Lee, MW Brechbiel, FE Smyth, LJ Old, AM Scott Clinical cancer research 6 (9), 3621-3628, 2000 | 95 | 2000 |
| Phase I biodistribution and pharmacokinetic study of Lewis Y–targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers RA Herbertson, NC Tebbutt, FT Lee, DJ MacFarlane, B Chappell, ... Clinical Cancer Research 15 (21), 6709-6715, 2009 | 86 | 2009 |
| Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma G Chong, FT Lee, W Hopkins, N Tebbutt, JS Cebon, AJ Mountain, ... Clinical Cancer Research 11 (13), 4818-4826, 2005 | 86 | 2005 |
| Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR C Panousis, VM Rayzman, TG Johns, C Renner, Z Liu, G Cartwright, ... British journal of cancer 92 (6), 1069-1077, 2005 | 81 | 2005 |
| In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice K Clarke, FT Lee, MW Brechbiel, FE Smyth, LJ Old, AM Scott Cancer research 60 (17), 4804-4811, 2000 | 81 | 2000 |
| Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity Z Liu, FE Smyth, C Renner, FT Lee, E Oosterwijk, AM Scott Cancer Immunology, Immunotherapy 51, 171-177, 2002 | 79 | 2002 |
| A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen AM Scott, N Tebbutt, FT Lee, T Cavicchiolo, Z Liu, S Gill, AMT Poon, ... Clinical cancer research 13 (11), 3286-3292, 2007 | 76 | 2007 |
| Synergies between micropreparative high-performance liquid chromatography and an instrumental optical biosensor E Nice, M Lackmann, F Smyth, L Fabri, AW Burgess Journal of Chromatography A 660 (1-2), 169-185, 1994 | 72 | 1994 |
| Biodistribution properties of 111Indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F (ab′) 2 constructs in a … K Tahtis, FT Lee, FE Smyth, BE Power, C Renner, MW Brechbiel, LJ Old, ... Clinical cancer research 7 (4), 1061-1072, 2001 | 62 | 2001 |
